

Figure 1


(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione



(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione.



(±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



(±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione






Figure 2.

(-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 0.62 μM

(+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 4.1 μM

Figure 3




(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
μM
Control
0.05
0.5
10
0.05
0.5
10


Figure 4



A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione


B= (+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 5



A= (±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione
B= (±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 6



A= (±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

B= (±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 7




Figure 8




Figure 9



Control
(-)-Trans 200mg/kg po qd
Mean Tumor Volume, mm
1400
1200
1000
800
600
400
200
0
0
8
11
15
18
22
25
32
37
39
44
47
51
Days Post Innoculation

Figure 10



Control
(-)-Trans 200mg/kg po qd
(-)-Trans 300mg/kg po qd
Mean Tumor Volume, mm
1800
1600
1400
1200
1000
800
600
400
200
0
0
8
12
15
19
22
26
29
33
37
40
Days Post Innoculation

Figure 11




control
(-)-Trans 200mg/kg po qd
(-)-Trans 300mg/kg po qd
Mean Tumor Volume, mm
1200
1000
800
600
400
200
0
0 17 20 24 27 33 38 42 46 49 54 59 63
Days Post Innoculation


Figure 12

Figure 1


(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione



(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione.



(±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



(±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione






Figure 2.

(-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 0.62 μM

(+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione



LC_{50} = 4.1 μM

Figure 3




(±)-cis-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
(±)-trans-3-(5,6-dihydro-4H-pyrrolo [3,2,1-ij] quinolin-1-yl)-4(1H-indol-3-yl) pyrrolidine-2, 5-dione
μM
Control
0.05
0.5
10
0.05
0.5
10


Figure 4



A= (-)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

B= (+)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione


Figure 5



A= (±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

B= (±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 6



A= (±)-cis-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

B= (±)-trans-3-(5,6-dihydro-4*H*-pyrrolo [3,2,1-*ij*] quinolin-1-yl)-4(1*H*-indol-3-yl) pyrrolidine-2, 5-dione

Figure 7




Figure 8




Figure 9



Control
(-)-Trans 200mg/kg po qd
Mean Tumor Volume, mm
1400
1200
1000
800
600
400
200
0
0
8
11
15
18
22
25
32
37
39
44
47
51
Days Post Innoculation

Figure 10



Control
(-)-Trans 200mg/kg po qd
(-)-Trans 300mg/kg po qd
Mean Tumor Volume, mm
1800
1600
1400
1200
1000
800
600
400
200
0
0
8
12
15
19
22
26
29
33
37
40
Days Post Innoculation

Figure 11



control
(-)-Trans 200mg/kg po qd
(-)-Trans 300mg/kg po qd
Mean Tumor Volume, mm
1200
1000
800
600
400
200
0
0 17 20 24 27 33 38 42 46 49 54 59 63
Days Post Innoculation

Figure 12